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Twenty-nine single-nucleotide polymorphisms (SNPs) from pre-
viously published genome-wide association studies (GWAS) and
multiple ancestry informative markers were genotyped in the
Carolina Breast Cancer Study (CBCS) (742 African-American
(AA) cases, 1230 White cases; 658 AA controls, 1118 White con-
trols). In the entire study population, 9/10 SNPs in fibroblast
growth factor receptor 2 (FGFR2) were significantly associated
with breast cancer after adjusting for age, race and European
ancestry [odds ratios (OR) range 1.17–1.81]. Associations were
observed for SNPs in FGFR2, LSP1, H19, TLR1/TLR6 and RELN
for AA; FGFR2, TNRC9, H19 and MAP3K1 for Whites; FGFR2,
TNRC9, Msc5A1 and chromosome 8q for women ‡50 years old
and FGFR2 and TNRC9 for women <50 years old. FGFR2 hap-
lotypes based upon rs11200014, rs2981579, rs1219648 and
rs2420946 were associated with increased risk of breast cancer,
including the GTGT haplotype in AAs [OR 5 1.27, 95% confi-
dence interval (CI) 1.04–1.56] and younger women of either race
[OR 5 1.35, 95% CI 1.02–1.78) and the ATGT haplotype in
Whites (OR 5 1.30, 95% CI 1.15–1.46). Recent GWAS hits for
breast cancer in Europeans and Whites (i.e. women of European
descent) thus showed evidence of replication among AAs and
Whites in the CBCS. Several new haplotypes were associated with
breast cancer in AA and younger women, particularly the FGFR2
GTGT haplotype. These results highlight the need to conduct
GWAS among younger women and in a variety of racial–ethnic
populations.
Introduction
Until recently, the search for reproducible common, low-penetrance
susceptibility genes for breast cancer yielded few positive findings
(1). A turning point was reached with the advent of genome-wide
association studies (GWAS) (2). Two GWAS of breast cancer
were published in 2007 using data collected from European and White
(i.e. of European descent) women (3,4). Easton et al. (3) discovered five
breast cancer susceptibility loci, including fibroblast growth factor
receptor 2 (FGFR2) on chromosome 10q26, TNRC9/TOX3 at 16q12,
MAP3K1 at 5q11, LSP1 at 11p15 and a locus on 8q. Hunter et al. (4)
confirmed an association between FGFR2 and sporadic postmeno-
pausal breast cancer and also identified additional susceptibility loci
at RELN on 7q and TLR1/TLR6 on 4p. More recent GWAS conducted
in European or Whites, and a few studies among Asians, have discov-
ered loci on chromosomes 2q25 (5,6), 6q22 (7), 6q25 (8), 3p24 and
17q23 (9), as well as 1p11 and 14q24 (10). Within these regions of
interest, relative risks ranging from 1.1 to 1.5 have been estimated for
single-nucleotide polymorphisms (SNPs) located in high linkage dis-
equilibrium (LD) blocks ranging in size from 25 to 600 kb. Minor allele
frequencies for SNPs showing the strongest signals range from 0.13 to
0.50, indicating that the alleles may contribute substantially to breast
cancer susceptibility on a population level (6).
Most previous GWAS of breast cancer focused on European or
White women and included primarily postmenopausal women. In
women under age 45, the incidence of breast cancer is higher
in African-American (AA) women compared with White women.
Among older women, breast cancer incidence is higher in Whites.
Breast cancer mortality is higher among AA women compared with
White women across all age groups (11). Identifying variants, partic-
ularly in key genes like FGFR2, that are specific to AAs or younger
women may aid in improving knowledge about breast cancer devel-
opment and clinically relevant pathways for targeted prevention (12).
However, to date, only three studies have addressed the role of FGFR2
in AAs (13–15) and few studies included younger women. AAs have
shorter LD blocks on average and exhibit greater haplotype diversity
compared with Europeans and Whites (6), which may facilitate de-
tection of additional risk haplotypes, mapping of GWAS loci and
location of potential causal alleles. Using the Carolina Breast Cancer
Study (CBCS), a population-based case–control of AA and White
women, we evaluated SNPs and haplotypes in FGFR2 and other pre-
vious GWAS-identified loci for their association with breast cancer.
We aimed to evaluate GWAS risk genotypes and/or haplotypes in AA
women and women diagnosed at age ,50.
Materials and methods
Study population
The CBCS is a population-based case–control study of breast cancer conducted
in North Carolina (16,17). Briefly, eligible cases included women ages 20–74
who were diagnosed with primary invasive breast cancer from 1993 to 2001
and lived within a 24 county study area. Cases were identified using rapid case
ascertainment in cooperation with the North Carolina Central Cancer Registry.
Randomized recruitment was used to oversample AAs and women ,50 years
of age (18). Women diagnosed with breast carcinoma in situ were also enrolled
in the study from 1996 to 2001. Eligible controls were women aged 20–74
years, residing within the study area, with no history of breast cancer and were
identified using Division of Motor Vehicles lists (for women ,65 years) and
Medicare records (for women aged 65–74 years). Controls were frequency
matched to cases according to race within 5 years age categories.
Women who agreed to participate in the study provided informed consent
and completed an in-home interview regarding known and suspected breast
cancer risk factors. Women were also asked to provide a 30 ml blood sample.
DNA was extracted from the blood samples and stored at 80C. The inter-
view participation rates for invasive cases and controls were 76 and 55%,
respectively, and for carcinoma in situ, cases and controls were 83 and 65%,
respectively.
Age was defined as age in years at breast cancer diagnosis for cases or at the
time of sampling for controls and was dichotomized as ,50 (younger)
and 50 (older) for analysis purposes. Self-identified race was reported by
each study participant during the study interview and was used to classify study
participants for statistical analyses. Of 3748 CBCS participants with genotyp-
ing data, 2293 identified themselves as Caucasian (61%) and 1400 self-
identified as AA (37%). Less than 2% of participants (N 5 53) reported that
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they were Hispanic, mixed race or other race/ethnicity. For regression analyses,
these women and the Caucasian women were grouped together as White.
Overall, 2311 cases (894 AA, 1417 White) and 2022 controls (788 AA, 1234
White) enrolled in the study and 2045 (89%) cases and 1818 (90%) controls
provided DNA for genotyping. For the present analysis, the dataset included
742 AA cases (387 AA cases 50 years of age and 355 AA cases ,50 years),
658 AA controls (344 AA controls 50 years of age and 314 AA controls ,50
years), 1230 White cases (619 White cases 50 years of age and 611 White
cases ,50 years) and 1118 White controls (607 White controls 50 years of
age and 511 White controls ,50 years). All study procedures involving human
subjects were approved by the University of North Carolina at Chapel Hill
Institutional Review Board and in accordance with an assurance filed with and
approved by the Department of Health and Human Services.
SNP selection
Previously reported SNPs showing associations with breast cancer in one or
more GWAS were selected for genotyping, including SNPs in CASP8, FGFR2,
TNRC9, LSP1, H19, Msc5A1, TLR1/TLR6, MAP3K1, RELN and markers on
chromosomes 2p, 2q35, 5p, 5q and 8q (Tables I and II) (3–10). A panel of 158
ancestry informative markers (AIMs) was chosen to be maximally informative
for distinguishing between African and European ancestries, which have been
shown to be the two relevant ancestral populations for AAs and Whites (i.e. of
European descent) (19–21) (supplementary Table 1 is available at Carcinogen-
esis Online). AIMs were selected to maximize the difference in allele frequen-
cies between ancestral populations and the Fisher’s information criterion (22)
for distinguishing between African and European ancestry, based upon ances-
tral allele frequencies from Yoruba in Ibadan, Nigeria and CEPH (Utah resi-
dents with ancestry from northern and western Europe) populations in HapMap
(www.hapmap.org). AIMs were prioritized based on having the highest Fish-
er’s information criterion values in the following order: 90% European/10%
African, 10% European/90% African and 50% European/50% African (sup-
plementary Table 1 is available at Carcinogenesis Online). This prioritization
allowed the AIMs to be chosen to represent the whole expected ancestral
distribution of this population.
Genotyping results and quality control
The SNPs in this study were genotyped as part of a larger panel of 1536 SNPs.
SNPs were chosen for replication of previous GWAS hits based upon the most
significant published findings in Europeans and Whites. Genotyping was per-
formed by the University of North Carolina Mammalian Genotyping Core using
the Illumina GoldenGate assay (Illumina, San Diego, CA). Assay intensity data
and genotype cluster images for all SNPs were reviewed individually. One
hundred and sixty-three SNPs were excluded from the dataset (11%) due to
low signal intensity or inability to distinguish between genotype clusters. Blind
duplicates of 169 samples were genotyped in order to verify the reproducibility
of genotype calls. No SNPs were excluded at this step (i.e. no SNP had .2
genotype call errors between blind duplicates). Exact tests of Hardy–Weinberg
equilibrium (HWE) were conducted in controls stratified by race to check for
potential genotyping errors, and HWE test statistics and P-values were calcu-
lated in Plink v1.05 (23). In order to confirm that HWE deviations were not due
to erroneous genotype calls, genotyping cluster images were rereviewed for all
SNPs with HWE P-values ,0.01. All but four SNPs rereviewed during this
process had acceptable signal intensity and genotype cluster definitions.
Overall, 1373 of 1536 (89%) SNPs passed quality control, including 2/2
(100%) for CASP8, 10/11 (91%) for FGFR2 and 17/17 (100%) for TNRC9,
LSP1, H19, Msc5A1, MAP3K1, RELN, TLR1/TLR6 and chromosomes 2p,
2q35, 5p, 5q and 8q. One hundred and forty-four of 158 (91%) AIMs passed
quality control. Participants were excluded because of genotype calls
for ,95% of SNPs (N 5 103), gender mismatch (N 5 5) and suspected con-
tamination (N 5 1). Following quality control, 1776 of 2022 (88%) controls
and 1972 of 2311 (85%) cases were successfully genotyped. Participants with-
out genotype data were more probably to be cases, recruited during later years
of the study and AA. Among cases, the presence of genotype data was not
associated with stage at diagnosis, lymph node status or other clinical variables.
Statistical analysis
Individual estimates of European ancestry were calculated from 144 AIMs
using maximum likelihood methods [as described in (19,20)] (supplementary
Table 1 is available at Carcinogenesis Online). Average and median propor-
tions of European ancestry were 0.93 and 0.94 for Whites and 0.22 and 0.19 for
AA, respectively (Figure 1). AIMs were selected to differentiate between
African and European ancestry only, so ancestry proportions for the two groups
add up to 1.0. Allele frequencies, genotype frequencies and D# (as a measure of
LD) were calculated using SAS Genetics (24).
All single SNP and haplotype analyses were performed for the total study
population and stratified by either self-reported race (AA or White) or age at
diagnosis (,50 or 50). All models were adjusted for age and/or race as
appropriate as well as individual European ancestry proportion. Individual
European ancestry proportion was included in all models in order to control
for potential residual confounding due to population stratification. An offset
term was also included in all models to account for the randomized recruitment
probabilities used to sample eligible study participants (15). Single SNP ge-
notypic associations with breast cancer were modeled using an unconditional
logistic regression model with two degrees of freedom (i.e. codominant
model). Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated
from these models for homozygote and heterozygote genotypes, as well as for
additive (per-allele) models. While the additive model is a special case nested
within the general codominant model, we present results using both models
because the codominant model makes no assumption of a dose–response re-
lationship across genotype categories and allows each genotype category to
give a different and non-additive risk. The additive model assumes homozy-
gotes have double the risk compared with heterozygotes on the log scale and
can be used as a test for linear trend. Results did not differ when we excluded
cases with in situ breast cancer or participants with mixed, Hispanic or other
race/ethnicities.
Haplotypes were estimated and tested for association with breast cancer risk
using haplo.stats (25). SNPs were selected for haplotype analysis if D# values
were 0.7 within any gene; hence haplotypes were estimated for FGFR2
using SNPs rs11200014, rs2981579, rs1219648 and rs2420946 (D# ranging from
0.822 to 1.000), TNRC9 using SNPs rs12443621 and rs3803662 (D# 5 0.714),
CASP8 using SNPs rs1045485 and rs17468277 (D# 5 0.999). For FGFR2,
haplotypes were estimated using the four SNPs listed above in order to directly
compare our results with previous studies (D# values between 0.82 and 1.0) (4).
Haplotypes were also estimated using other genotyped SNPs in FGFR2 and
results were similar since these SNPs were in strong LD with the four SNP
haplotype (data not shown). In addition, these four SNPs in FGFR2 are all in
strong LD with each other, including rs2981582, which is the original SNP found
to be associated with increased risk of breast cancer in women of European
ancestry (3,4). The most common haplotype (GCAC) was associated with
lower breast cancer risk compared with the other haplotypes and designated
the reference group.
Maximum likelihood estimates of haplotype frequencies and the posterior
probabilities of the pairs of haplotypes for each individual were calculated
using the expectation–maximization algorithm as implemented in haplo.stats
(26). The posterior probabilities were then incorporated into generalized linear
models to compute the score statistics for the association between a haplotype
and breast cancer risk. The most common haplotype for each locus formed the
reference group. ORs and 95% CIs were calculated from these models, adjust-
ing for age and/or race as appropriate, individual European ancestry proportion
and offset term. Haplotype P-values were two sided and were derived from the
t-statistic using the beta coefficient in logistic regression models with a signif-
icance level of 0.05. Rare haplotypes with a frequency ,0.5% were binned as
a group of rare haplotypes, but associations for this group are not reported due
to the difficulty in deriving meaningful interpretations.
Results
In the entire study population, combining AA and White study par-
ticipants, the minor alleles in nine of 10 SNPs in FGFR2 were sig-
nificantly associated with increased odds of breast cancer using
codominant and additive models after adjusting for age, race,
European ancestry and study offset term with adjusted ORs ranging
from 1.17 to 1.81 (supplementary Table 2 is available at Carcinogen-
esis Online). Variants in SNPs in TNRC9 (rs8051542 and rs3803662)
and TLR1/TLR6 (rs7696175) were also associated with increased risk
of breast cancer in the entire study population. No associations were
observed for SNPs in CASP8, LSP1, H19, Msc5A1, MAP3K1, RELN
or loci on chromosomes 2p, 2q35, 5p, 5q or 8q. In the haplotype
analysis for the entire study population, only haplotypes in FGFR2
showed positive associations with breast cancer. Three FGFR2 hap-
lotypes (ATGT, GTGT and GTAT) were associated with increased
odds of breast cancer after controlling for race, age, European ances-
try and study offset term (supplementary Table 3 is available at
Carcinogenesis Online).
Single SNP results adjusted for age, European ancestry and study
offset term stratified by self-reported race are presented in Table I (see
supplementary Table 4, available at Carcinogenesis Online, for geno-
type frequencies stratified by self-reported race). Per-allele ORs for
FGFR2 using an additive model were slightly stronger in White
J.S.Barnholtz-Sloan et al.
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compared with AA women, and 8/10 loci were statistically significant
in AA and 9/10 among White women. Among AA women, positive
per-allele associations were observed for H19 (rs2107425) and TLR1/
TLR6 (rs7696175), and significant but imprecise associations were
observed for homozygotes carrying the less common allele for
LSP1 (rs3817198) and RELN (rs17157903). For White women, pos-
itive per-allele associations were observed for TNRC9 (rs3803662)
and MAP3K1 (rs889312), whereas inverse per-allele association
was found for TNRC9/TOX3 (rs12443621) and H19 (rs2107425). Sin-
gle SNP results adjusted for age, race, European ancestry and study
offset term and stratified by age at diagnosis (,50, 50 years) are
presented in Table II (see supplementary Table 4, available at Carci-
nogenesis Online, for genotype frequencies stratified by age at diag-
nosis). In general, per-allele ORs for FGFR2 SNPs were stronger for
Table I. Single SNP results stratified by self-reported race











AA CASP8 rs1045485 C/G 0.96 (0.68–1.36) 0.45 (0.05–3.74) 0.93 (0.67–1.30)
rs17468277 T/C 0.96 (0.67–1.37) 0.24 (0.02–3.28) 0.92 (0.65–1.29)
FGFR2 rs1896395 A/C 0.87 (0.69–1.10) 1.69 (0.94–3.07) 1.01 (0.83–1.23)
rs11200014 A/G 1.00 (0.79–1.27) 1.23 (0.71–2.11) 1.04 (0.86–1.26)
rs2981579 T/C 1.39 (1.02–1.90) 1.54 (1.12–2.13) 1.22 (1.04–1.42)
rs1219648 G/A 1.13 (0.89–1.45) 1.45 (1.05–1.99) 1.19 (1.02–1.39)
rs2912774 A/C 1.05 (0.78–1.41) 1.55 (1.13–2.13) 1.27 (1.09–1.49)
rs2936870 T/C 1.05 (0.78–1.41) 1.54 (1.12–2.11) 1.27 (1.09–1.48)
rs2981582 T/C 1.30 (1.00–1.68) 1.40 (1.02–1.91) 1.19 (1.02–1.39)
rs2420946 T/C 1.02 (0.77–1.35) 1.36 (0.99–1.86) 1.17 (1.00–1.37)
rs2162540 G/A 1.19 (0.91–1.56) 1.51 (1.11–2.06) 1.23 (1.05–1.44)
rs3135718 G/A 1.11 (0.83–1.48) 1.54 (1.14–2.10) 1.26 (1.08–1.46)
TNRC9 3# UTR rs8049149 C/T 0.93 (0.55–1.59) 0.69 (0.04–11.25) 0.92 (0.56–1.52)
TNRC9 5# UTR rs16951186 C/T 0.81 (0.63–1.03) 1.10 (0.61–1.97) 0.90 (0.74–1.09)
TNRC9/TOX3 rs8051542 C/T 1.04 (0.83–1.31) 1.45 (0.99–2.11) 1.14 (0.97–1.35)
TNRC9/TOX3 rs12443621 G/A 1.21 (0.92–1.58) 1.35 (0.99–1.83) 1.16 (0.99–1.35)
TNRC9 5# UTR rs3803662 C/T 0.97 (0.74–1.29) 0.90 (0.66–1.23) 0.95 (0.81–1.11)
TNRC9 rs9940048 G/A 1.20 (0.96–1.51) 1.07 (0.71–1.61) 1.10 (0.93–1.31)
LSP1 rs3817198 C/T 1.19 (0.93–1.52) 0.47 (0.23–0.99) 1.01 (0.82–1.24)
H19 rs2107425 T/C 1.31 (1.00–1.73) 1.43 (1.04–1.97) 1.20 (1.02–1.40)
Msc5A1 rs6476643 T/G 1.13 (0.89–1.42) 1.21 (0.68–2.15) 1.12 (0.92–1.36)
TLR1/TLR6 rs7696175 T/C 1.22 (0.88–1.71) 4.11 (1.28–13.24) 1.39 (1.04–1.86)
MAP3K1 rs889312 C/A 1.00 (0.79–1.25) 0.84 (0.57–1.25) 0.95 (0.80–1.13)
RELN rs17157903 T/C 0.87 (0.66–1.16) 5.21 (1.48–18.29) 1.07 (0.83–1.37)
Chromosome 2p rs4666451 A/G 1.03 (0.82–1.30) 0.48 (0.28–0.81) 0.87 (0.72–1.05)
Chromosome 2q35 rs13387042 G/A 1.00 (0.80–1.26) 0.91 (0.58–1.43) 0.98 (0.82–1.17)
Chromosome 5p rs981782 G/T 0.86 (0.63–1.17) 1.10 (0.39–3.16) 0.90 (0.68–1.19)
Chromosome 5q rs30099 T/C 1.26 (0.98–1.62) 1.28 (0.59–2.74) 1.22 (0.98–1.52)
Chromosome 8q rs13281615 G/A 1.14 (0.89–1.46) 0.97 (0.70–1.34) 1.00 (0.86–1.18)
White CASP8 rs1045485 C/G 0.92 (0.75–1.13) 0.75 (0.4–1.42) 0.90 (0.76–1.08)
rs17468277 T/C 0.92 (0.75–1.13) 0.75 (0.4–1.42) 0.91 (0.76–1.08)
FGFR2 rs1896395 A/C 1.51 (0.45–5.03) 2.14 (0.78–5.92)
rs11200014 A/G 1.30 (1.07–1.58) 1.63 (1.27–2.10) 1.28 (1.13–1.45)
rs2981579 T/C 1.36 (1.12–1.66) 1.71 (1.33–2.19) 1.31 (1.16–1.48)
rs1219648 G/A 1.35 (1.11–1.63) 1.65 (1.28–2.12) 1.30 (1.15–1.46)
rs2912774 A/C 1.39 (1.14–1.68) 1.63 (1.27–2.09) 1.29 (1.14–1.46)
rs2936870 T/C 1.38 (1.14–1.67) 1.64 (1.27–2.11) 1.30 (1.15–1.46)
rs2981582 T/C 1.37 (1.13–1.66) 1.62 (1.26–2.09) 1.29 (1.14–1.46)
rs2420946 T/C 1.38 (1.14–1.67) 1.62 (1.25–2.08) 1.29 (1.14–1.46)
rs2162540 G/A 1.35 (1.12–1.64) 1.63 (1.26–2.10) 1.29 (1.14–1.46)
rs3135718 G/A 1.40 (1.15–1.69) 1.64 (1.28–2.12) 1.30 (1.15–1.47)
TNRC9 3# UTR rs8049149 C/T 0.84 (0.10–6.81) 0.84 (0.10–6.81)
TNRC9 5# UTR rs16951186 C/T 1.14 (0.63–2.04) 1.14 (0.63–2.04)
TNRC9/TOX3 rs8051542 C/T 0.92 (0.76–1.12) 0.26 (0.98–1.61) 1.10 (0.97–1.24)
TNRC9/TOX3 rs12443621 G/A 0.75 (0.61–0.93) 0.74 (0.58–0.95) 0.87 (0.77–0.98)
TNRC9 5# UTR rs3803662 C/T 1.20 (1.00–1.44) 1.64 (1.20–2.23) 1.25 (1.09–1.42)
TNRC9 rs9940048 G/A 1.07 (0.89–1.28) 1.01 (0.70–1.48) 1.04 (0.90–1.20)
LSP1 rs3817198 C/T 1.04 (0.87–1.25) 1.27 (0.94–1.71) 1.07 (0.96–1.25)
H19 rs2107425 T/C 0.90 (0.75–1.07) 0.70 (0.52–0.96) 0.86 (0.75–0.98)
Msc5A1 rs6476643 T/G 1.07 (0.89–1.28) 0.88 (0.61–1.25) 1.00 (0.87–1.15)
TLR1/TLR6 rs7696175 T/C 0.96 (0.78–1.16) 1.20 (0.93–1.53) 1.08 (0.95–1.22)
MAP3K1 rs889312 C/A 1.06 (0.88–1.27) 1.57 (1.16–2.13) 1.18 (1.03–1.34)
RELN rs17157903 T/C 0.86 (0.70–1.06) 0.79 (0.46–1.38) 0.87 (0.73–1.03)
Chromosome 2p rs4666451 A/G 1.05 (0.87–1.27) 0.96 (0.74–1.24) 0.99 (0.88–1.13)
Chromosome 2q35 rs13387042 G/A 0.92 (0.75–1.12) 0.88 (0.68–1.12) 0.93 (0.83–1.06)
Chromosome 5p rs981782 G/T 0.96 (0.78–1.18) 1.05 (0.82–1.35) 1.02 (0.90–1.15)
Chromosome 5q rs30099 T/C 1.07 (0.85–1.34) 0.79 (0.33–1.89) 1.03 (0.84–1.26)
Chromosome 8q rs13281615 G/A 1.17 (0.97–1.43) 1.23 (0.95–1.58) 1.12 (0.99–1.26)
aAdjusted for age, European ancestry and offset term.
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older compared with younger women, with very few other single
SNPs showing a positive association with breast cancer risk in either
age group.
ORs for haplotypes adjusted for age, European ancestry and study
offset term stratified by self-reported race are presented in Table III.
Among AA women, only the FGFR2 GTGT haplotype (based upon
rs11200014, rs2981579, rs1219648 and rs2420946) was positively
associated with breast cancer (OR 5 1.27, 95% CI 1.04–1.56). The
FGFR2 GTGT haplotype was present in 23.1% of AAs (24.6% of AA
cases and 21.4% of AA controls) but only 0.6% of Whites (0.8% of
White cases and 0.6% of White controls). Among White women, only
the FGFR2 ATGT haplotype showed a positive association with
breast cancer (OR 5 1.30, 95% CI 1.15–1.46) and was present in
39.4% of participants (42.1% of White cases and 39.2% of White
Table II. Single SNP analysis stratified by age at diagnosis











Age  50 CASP8 rs1045485 C/G 0.80 (0.62–1.03) 0.86 (0.35–2.13) 0.83 (0.66–1.03)
rs17468277 T/C 0.79 (0.62–1.02) 0.82 (0.32–2.06) 0.82 (0.65–1.02)
FGFR2 rs1896395 A/C 0.97 (0.71–1.34) 1.76 (0.81–3.83) 1.10 (0.85–1.43)
rs11200014 A/G 1.43 (1.16–1.77) 1.65 (1.20–2.26) 1.32 (1.14–1.53)
rs2981579 T/C 1.66 (1.31–2.10) 1.90 (1.44–2.49) 1.38 (1.20–1.58)
rs1219648 G/A 1.46 (1.18–1.80) 1.78 (1.35–2.35) 1.35 (1.18–1.55)
rs2912774 A/C 1.43 (1.14–1.79) 1.95 (1.49–2.56) 1.40 (1.22–1.60)
rs2936870 T/C 1.45 (1.15–1.82) 1.94 (1.48–2.55) 1.40 (1.22–1.60)
rs2981582 T/C 1.52 (1.23–1.89) 1.77 (1.35–2.34) 1.36 (1.18–1.55)
rs2420946 T/C 1.47 (1.18–1.83) 1.81 (1.38–2.37) 1.35 (1.18–1.55)
rs2162540 G/A 1.49 (1.20–1.86) 1.89 (1.44–2.48) 1.39 (1.21–1.59)
rs3135718 G/A 1.53 (1.22–1.92) 1.96 (1.50–2.56) 1.41 (1.23–1.61)
TNRC9 3# UTR rs8049149 C/T 0.81 (0.37–1.79) 0.98 (0.47–2.06)
TNRC9 5# UTR rs16951186 C/T 0.90 (0.66–1.23) 1.11 (0.50–2.47) 0.93 (0.72–1.21)
TNRC9/TOX3 rs8051542 C/T 0.80 (0.65–0.99) 1.58 (1.18–2.11) 1.14 (0.99–1.31)
TNRC9/TOX3 rs12443621 G/A 0.98 (0.77–1.23) 1.00 (0.77–1.30) 1.02 (0.89–1.16)
TNRC9 5# UTR rs3803662 C/T 1.05 (0.85–1.30) 1.06 (0.78–1.42) 1.03 (0.89–1.19)
TNRC9 rs9940048 G/A 1.18 (0.97–1.43) 1.08 (0.73–1.60) 1.10 (0.94–1.28)
LSP1 rs3817198 C/T 0.98 (0.80–1.21) 1.00 (0.68–1.46) 1.00 (0.85–1.16)
H19 rs2107425 T/C 1.05 (0.85–1.29) 0.82 (0.61–1.11) 0.95 (0.82–1.09)
Msc5A1 rs6476643 T/G 1.23 (1.01–1.50) 0.93 (0.61–1.40) 1.07 (0.91–1.25)
TLR1/TLR6 rs7696175 T/C 0.95 (0.75–1.20) 0.88 (0.63–1.23) 0.96 (0.82–1.12)
MAP3K1 rs889312 C/A 1.13 (0.92–1.38) 1.05 (0.75–1.47) 1.06 (0.92–1.22)
RELN rs17157903 T/C 0.87 (0.69–1.10) 1.40 (0.70–2.78) 0.94 (0.77–1.15)
Chromosome 2p rs4666451 A/G 0.98 (0.80–1.21) 0.81 (0.59–1.12) 0.93 (0.80–1.07)
Chromosome 2q35 rs13387042 G/A 0.97 (0.79–1.02) 0.85 (0.63–1.14) 0.93 (0.81–1.07)
Chromosome 5p rs981782 G/T 0.96 (0.76–1.22) 1.20 (0.86–1.67) 1.07 (0.91–1.25)
Chromosome 5q rs30099 T/C 1.27 (1.00–1.62) 0.99 (0.48–2.05) 1.18 (0.96–1.46)
Chromosome 8q rs13281615 G/A 1.29 (1.04–1.59) 1.28 (0.97–1.70) 1.15 (1.01–1.32)
Age , 50 CASP8 rs1045485 C/G 1.10 (0.85–1.42) 0.64 (0.27–1.49) 1.01 (0.81–1.27)
rs17468277 T/C 1.10 (0.85–1.43) 0.64 (0.27–1.49) 1.01 (0.81–1.27)
FGFR2 rs1896395 A/C 0.81 (0.58–1.13) 2.07 (0.84–5.11) 0.99 (0.74–1.31)
rs11200014 A/G 0.96 (0.77–1.19) 1.35 (0.98–1.86) 1.10 (0.95–1.28)
rs2981579 T/C 1.16 (0.91–1.47) 1.39 (1.05–1.84) 1.18 (1.03–1.36)
rs1219648 G/A 1.10 (0.88–1.38) 1.37 (1.03–1.84) 1.16 (1.01–1.34)
rs2912774 A/C 1.16 (0.92–1.46) 1.40 (1.06–1.86) 1.18 (1.03–1.36)
rs2936870 T/C 1.13 (0.89–1.42) 1.42 (1.07–1.89) 1.19 (1.03–1.37)
rs2981582 T/C 1.21 (0.97–1.51) 1.30 (0.98–1.74) 1.15 (1.00–1.33)
rs2420946 T/C 1.08 (0.86–1.36) 1.32 (0.99–1.75) 1.14 (0.99–1.32)
rs2162540 G/A 1.14 (0.91–1.43) 1.34 (1.01–1.78) 1.16 (1.00–1.33)
rs3135718 G/A 1.12 (0.89–1.41) 1.39 (1.05–1.84) 1.18 (1.02–1.35)
TNRC9 3# UTR rs8049149 C/T 1.02 (0.51–2.04) 0.87 (0.45–1.65)
TNRC9 5# UTR rs16951186 C/T 0.81 (0.58–1.13) 1.21 (0.51–2.90) 0.94 (0.72–1.24)
TNRC9/TOX3 rs8051542 C/T 1.16 (0.93–1.44) 1.14 (0.84–1.53) 1.08 (0.93–1.24)
TNRC9/TOX3 rs12443621 G/A 0.83 (0.65–1.05) 0.85 (0.64–1.12) 0.92 (0.80–1.06)
TNRC9 5# UTR rs3803662 C/T 1.26 (1.01–1.57) 1.41 (1.05–1.91) 1.20 (1.04–1.39)
TNRC9 rs9940048 G/A 1.07 (0.87–1.32) 1.04 (0.70–1.54) 1.02 (0.87–1.19)
LSP1 rs3817198 C/T 1.17 (0.95–1.45) 1.27 (0.86–1.88) 1.14 (0.98–1.33)
H19 rs2107425 T/C 0.94 (0.75–1.17) 1.10 (0.81–1.51) 1.02 (0.88–1.18)
Msc5A1 rs6476643 T/G 0.99 (0.80–1.22) 1.06 (0.67–1.66) 1.02 (0.86–1.20)
TLR1/TLR6 rs7696175 T/C 1.12 (0.88–1.44) 1.84 (1.32–2.58) 1.28 (1.09–1.49)
MAP3K1 rs889312 C/A 0.94 (0.76–1.15) 1.50 (1.05–2.15) 1.12 (0.94–1.30)
RELN rs17157903 T/C 0.84 (0.66–1.08) 1.15 (0.58–2.30) 0.91 (0.74–1.11)
Chromosome 2p rs4666451 A/G 1.08 (0.87–1.34) 0.89 (0.64–1.24) 0.99 (0.85–1.14)
Chromosome 2q35 rs13387042 G/A 0.94 (0.75–1.17) 0.91 (0.67–1.23) 0.95 (0.82–1.10)
Chromosome 5p rs981782 G/T 0.88 (0.68–1.12) 0.91 (0.65–1.28) 0.94 (0.80–1.11)
Chromosome 5q rs30099 T/C 1.06 (0.83–1.35) 1.05 (0.40–2.75) 1.05 (0.84–1.31)
Chromosome 8q rs13281615 G/A 1.06 (0.84–1.32) 0.94 (0.74–1.25) 1.00 (0.87–1.15)
aAdjusted for age, race, European ancestry and offset term.
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controls). The FGFR2 ATGT haplotype was present in 15.8% of AA
participants (15.8% of AA cases and 15.9% of AA controls). Addi-
tionally, among White women, the TNRC9 GT haplotype (based upon
rs12443621 and rs3803662) was associated with increased odds of
breast cancer (OR 5 1.25, 95% CI 1.09–1.42) and was common in all
study participants (28.5% of Whites and 40.4% of AAs).
Haplotype analyses adjusted for age, race, European ancestry and
study offset term and stratified by age at diagnosis are presented in Table
IV. Among women aged 50, the CASP8 CT haplotype (based upon
rs1045485 and rs17468277) was associated with decreased odds of
breast cancer (OR 5 0.79, 95% CI 0.64–0.98). The TNRC9 GT haplo-
type was associated with increased odds of breast cancer among younger
(OR 5 1.17, 95% CI 1.01–1.36) but not older women. The FGFR2
ATGT (OR 5 1.37, 95% CI 1.18–1.58) and GTGT (OR 5 1.39, 95%
CI 1.08–1.80) haplotypes were positively associated with breast cancer
in older women. Among younger women, only the FGFR2 GTGT
haplotype (OR 5 1.35, 95% CI 1.02–1.78) was associated with breast
cancer. In older women, 30.2% had the ATGT haplotype (32.5% of
cases and 33.8% of controls) and 9.0% had the GTGT haplotype
(9.8% of cases and 5.2% of controls). In younger women, 31.2% had
the ATGT haplotype (32.3% of cases and 34.8% of controls) and 8.8%
had the GTGT haplotype (9.4% of cases and 5.0% of controls). In AA
women, the GTGT haplotype was more strongly associated with breast
cancer risk in older women (OR 5 1.34, 95% CI 1.01–1.76) compared
with younger women (OR 5 1.20, 95% CI 0.89–1.62). In White
women, the ATGT haplotype was more strongly associated with breast
cancer risk in older women (OR 5 1.42, 95% CI 1.23–1.64) compared
with younger women (OR 5 1.19, 95% CI 1.02–1.39).
Discussion
We investigated the role of FGFR2 and other loci identified in breast
cancer GWAS using a population-based case–control study that in-
cluded large proportions of AA and younger study participants. Our
results replicate previous findings for FGFR2 and contribute new in-
formation for AA and younger women (diagnosed at age ,50).
Our results for the FGFR2 ATGT haplotype in the overall study
population (OR 5 1.25, 95% CI 1.15–1.36) and in Whites only
(OR 5 1.30, 95% CI 1.15–1.46) are similar to the results of Hunter
et al. (4). Hunter et al. (4) used four SNPs (rs11200014, rs2981579,
rs1219648 and rs2420946) to identify high- and low-risk FGFR2
intron 2 haplotypes, given that the strongest signal in a previous
Table III. Haplotype results stratified by self-reported race







AA CASP8b GC 94.1 Reference —
CT 5.3 0.91 (0.65–1.27) 0.58
FGFR2c GCAC 35.4 Reference —
ATGT 15.8 1.11 (0.88–1.39) 0.38
GTGT 23.1 1.27 (1.04–1.56) 2.05E-02
GTAC 7.4 1.08 (0.78–1.49) 0.66
GTAT 8.9 1.25 (0.93–1.67) 0.14
ATAC 3.2 1.11 (0.68–1.80) 0.68
GCAT 2.2 0.77 (0.43–1.38) 0.38
GCGT 2.4 1.10 (0.65–1.89) 0.72
TNRC9d AC 39.5 Reference —
AT 12.0 1.01 (0.77–1.31) 0.96
GC 7.9 0.83 (0.61–1.13) 0.24
GT 40.4 0.91 (0.77–1.07) 0.25
White CASP8b GC 86.9 Reference —
CT 13.1 0.90 (0.76–1.07) 0.24
FGFR2c GCAC 55.7 Reference —
ATGT 39.4 1.30 (1.15–1.46) 1.91E-05
ATAC 2.0 1.32 (0.87–2.01) 0.19
ATGC 1.1 1.00 (0.57–1.75) 1.00
TNRC9d AC 49.6 Reference —
AT 1.2 0.66 (0.35–1.22) 0.18
GC 20.7 1.01 (0.87–1.18) 0.87
GT 28.5 1.25 (1.09–1.42) 1.37E-03
aAdjusted for age, European ancestry and offset term.
bCASP8 SNPs are rs1045485 and rs17468277 in relative nucleotide location
order.
cFGFR2 SNPs are rs11200014, rs2981579, rs1219648 and rs2420946 in
relative nucleotide location order.
dTNRC9 SNPs are rs12443621 and rs3803662 in relative nucleotide location
order.
Fig. 1. Distribution of individual maximum likelihood estimates (MLEs) of
European ancestry proportions by self-reported race; AA.
Table IV. Haplotype results stratified by age at diagnosis







Age  50 CASP8b GC 89.7 Reference —
CT 10.0 0.79 (0.64–0.98) 0.03
FGFR2c GCAC 48.3 Reference —
ATGT 30.2 1.37 (1.18–1.58) 2.51E-05
GTGT 9.0 1.39 (1.08–1.80) 0.01
GTAC 2.9 1.25 (0.83–1.87) 0.29
GTAT 3.9 1.29 (0.90–1.86) 0.16
ATAC 2.2 1.55 (0.98–2.44) 0.06
GCAT 1.0 0.85 (0.43–1.68) 0.63
ATGC 1.3 1.35 (0.75–2.45) 0.32
TNRC9d AC 45.9 Reference —
AT 5.6 0.96 (0.70–1.33) 0.82
GC 16.6 0.95 (0.79–1.15) 0.61
GT 31.8 1.03 (0.89–1.19) 0.69
Age , 50 CASP8b GC 89.5 Reference —
CT 10.3 1.04 (0.84–1.29) 0.74
FGFR2c GCAC 48.0 Reference —
ATGT 31.2 1.14 (0.98–1.32) 0.10
GTGT 8.8 1.35 (1.02–1.78) 0.03
GTAC 3.1 0.99 (0.64–1.53) 0.95
GTAT 3.0 1.30 (0.85–1.99) 0.22
ATAC 2.4 1.01 (0.64–1.59) 0.98
GCAT 1.1 0.61 (0.31–1.22) 0.16
GCGT 1.2 0.80 (0.43–1.48) 0.47
TNRC9d AC 44.9 Reference —
AT 5.5 1.10 (0.79–1.54) 0.58
GC 16.0 0.97 (0.79–1.19) 0.76
GT 33.5 1.17 (1.01–1.36) 0.04
aAdjusted for age, race, European ancestry and offset term.
bCASP8 SNPs are rs1045485 and rs17468277 in relative nucleotide location
order.
cFGFR2 SNPs are rs11200014, rs2981579, rs1219648 and rs2420946 in
relative nucleotide location order.
dTNRC9 SNPs are rs12443621 and rs3803662 in relative nucleotide location
order.
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GWAS was in a LD block of 25 kb in intron 2, which is thought to
mediate differential expression of FGFR2 (3). A positive association
was observed for the AAGT haplotype pooled across several studies
(OR 5 1.26, 95% CI 1.17–1.35) (4). Positive signals were not found
elsewhere in the gene or in neighboring regions. The authors desig-
nated the rs2981579 alleles (the second SNP in the FGFR2 haplotype)
using antisense coding, so that the GGAC haplotype in Hunter et al.
(4) corresponds to GCAC in our study and AAGT corresponds to
ATGT. However, the biological/functional significance of these hap-
lotypes as they relate to breast cancer risk is unknown. Causal alleles
in FGFR2 remain to be identified, but variation in rs7895676 and
rs2981578 in FGFR2 intron 2 was found to be associated with in-
creased FGFR2 expression (26). rs2981578 is in close proximity to
and in strong LD with rs2981579, which is included in our four
SNP FGFR2 intron 2 haplotype, and this was also reported by Hunter
et al. (4).
In addition, we detected a FGFR2 intron 2 haplotype in AAs
(GTGT) that was associated with increased risk of breast cancer
(OR 5 1.27, 95% CI 1.04–1.56). Three previous studies have ad-
dressed the role of FGFR2 in AAs (13–15). Udler et al. (13) em-
ployed dense SNP mapping and targeted resequencing to further
narrow and characterize the region of interest in FGFR2 intron 2
in AAs. The authors employed a regression approach to calculate
likelihood ratios for observed as well as imputed SNP genotypes and
detected the strongest signal for the SNP rs2981578 among 1253 AA
breast cancer cases and 1245 AA controls from four US epidemio-
logic studies. In the CBCS, the breast cancer-associated haplotypes
in FGFR2 intron 2 (ATGT, GTGT and GTAT) shared the T allele at
rs2981579, providing further evidence for a potential causal locus in
this region. Rebbeck et al. (14) found no association for two SNPs in
FGFR2 intron 2 (rs1219648 and rs2981582) in 157 AA cases and
427 controls. Zheng et al. (15) examined the role of 6 SNPs in
FGFR2 in 810 AA cases and 1784 controls and observed a positive
association for rs1219648, which is also included in our four SNP
FGFR2 intron 2 haplotype.
In the two other studies of AAs, Rebbeck et al. (14) reported
a positive association for MAP3K1 (rs889312), whereas Zheng et al.
(15) reported a positive association for chromosome 2q35
(rs13387042). While our study evaluated these SNPs in the AA
women in CBCS, we did not replicate these previous results at these
loci but instead found new associations at H19 (rs2107425) and TLR1/
TLR6 (rs7696175). Additional studies of AAs are needed in order to
increase sample size and achieve sufficient power to examine the role
of GWAS-identified loci among AAs. The combined sample size of
the four published studies of FGFR2 and other GWAS loci in AAs
[CBCS, Udler et al. (13), Rebbeck et al. (14), Zheng et al. (15)] is
2962 cases and 4114 controls compared with much larger studies of
Europeans and Whites (i.e. women of European descent) [e.g.
.25 000 cases and .25 000 controls in a validation study by Gaudet
et al. (27)].
We also evaluated the association between these GWAS SNPs and
risk of breast cancer for young women (diagnosed age ,50). While
both the FGFR2 ATGT and GTGT haplotypes were associated with
breast cancer in older women (ATGT: OR 5 1.37, 95% CI 1.18–1.58;
GTGT: OR 5 1.39, 95% CI 1.08–1.80), only the GTGT haplotype
was associated with breast cancer among younger women (OR
5 1.35, 95% CI 1.02–1.78). In addition, we found that the CASP8
CT haplotype was associated with decreased odds of breast cancer
(OR 5 0.79, 95% CI 0.64–0.98) in older women only, whereas the
TNRC9 GT haplotype was associated with breast cancer among youn-
ger women only (OR 5 1.17, 95% CI 1.01–1.36). The same haplo-
types were associated with disease risk when age-specific results were
further stratified by race (data not shown). While our results are sug-
gestive, none of the GWAS studies presented results for younger
women to which we can compare our results.
Our analysis was based on previously published GWAS papers
that included mainly postmenopausal European or White women.
We did not attempt to identify tagSNPs for FGFR2 or other loci
among AAs, as our goal was limited to replication of GWAS hits
previously reported for Whites. There may be other relevant SNPs
within these loci that are associated with breast cancer, particularly
for AA and younger women, that were not examined. In addition,
our sample size was relatively small for AAs. Future research will
require pooling of data from AAs breast cancer studies, particularly
for fine mapping of GWAS hits and to study gene–gene and gene–
environment interaction. Strengths of our analysis include the pop-
ulation-based study design of the CBCS, a study that includes a large
group of AA and a large group of women ,50, which affords the
necessary statistical power to examine genetic associations within
these subgroups. We utilized individual European ancestry estimates
derived from 144 AIMs, chosen to robustly distinguish between
European and African ancestry, in order to control for potential re-
sidual population stratification. Failure to adjust for population ad-
mixture can result in false-positive and false-negative associations
(as reviewed in ref. 20). In our study, the SNP effect estimates
changed by up to 43% and haplotype effect estimates changed by
up to 7% with the inclusion of ancestry information (data not
shown). The strongest effects of ancestry adjustment were seen for
the following SNPs: the effect estimates for rs1896395 in FGFR2 in
Whites changed from OR 5 1.077 to OR 5 1.509 in the codomi-
nant heterozygous model and from OR 5 1.502 to OR 5 2.143 in
the additive model after including the ancestry estimates. For
TNRC9 in Whites, the effect estimate for haplotype AT changed
from OR 5 0.611 to OR 5 0.655 after adjustment for ancestry.
The majority of effect estimates changed by 0.5% due to the an-
cestry adjustment.
In conclusion, we demonstrated that recent GWAS hits for breast
cancer in Europeans and Whites showed evidence of replication
among AAs and Whites in the CBCS. We identified several new
haplotypes that were associated with breast cancer in AA and younger
women, particularly the FGFR2 GTGT haplotype. Our results and
those of the three previously published studies of FGFR2 in AAs
(13–15) highlight the need to conduct GWAS and GWAS validation
in a variety of racial–ethnic populations as well as among younger
women.
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